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RENAL DISEASE ON CHRONIC HEMODIALYSIS: IS IT POSSIBLE 
OR IS IT INACCURACY OF TESTING?
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Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are at a high risk of acquiring SARS-CoV-2 and of 
developing severe COVID-19 and death. The possibility of being reinfected with this virus is poorly understood. To date, 
there are a small number of reports of reinfections in COVID-19 patients, especially in HD patients, with only four cases 
described so far. The aim was to show the possibility of reinfection and developing severe acute respiratory syndrome in 
HD patients. We describe a 69-year-old ESRD patient who had been on HD treatment for three years, with diabetes mellitus 
and a history of ischemic cardiomyopathy. The patient was tested for SARS-CoV-2 by a nasopharyngeal polymerase chain 
reaction (PCR) test because of a positive cluster at his dialysis unit and initially diagnosed with COVID-19 in July 2020. In 
this period, he had mild symptoms for a few days and remained asymptomatic afterwards. Four months later, he presented 
to the hospital with fatigue, high fever and shortness of breath, and was COVID-19 positive again. This case points to the 
possibility of reinfection, lack of immune response after an asymptomatic or mild infection, or even the possibility of the 
fi rst false-positive PCR test. Future longitudinal studies are needed to evaluate the potential reinfections, recurrence, and 
duration of antibody detection.
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INTRODUCTION
In December 31, 2019, the World Health Organization 
(WHO) China country offi  ce notifi ed of the cases of 
pneumonia of unknown etiology detected in Wuhan 
city, Hubei province, with subsequent detection of a 
new strain of coronavirus on January 7, 2020. Th e virus 
was subsequently named by the WHO as severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), 
and the disease caused by it as COVID-19. COVID-19 
has evolved into a global pandemic as declared by the 
WHO on March 11, 2020 (1), and caused over 15 mil-
lion infections and half a million deaths worldwide (2).
Patients with chronic kidney disease (CKD) and those 
on renal replacement therapies are potentially suscep-
tible to developing COVID-19 infection, given the 
concentration of the risk factors and comorbidities 
(3). Patients on chronic hemodialysis (HD) have a 
high risk of both infection and severe disease because 
of their fragility and unavoidable health care-related 
contacts. Th e diagnosis may be challenging; false-neg-
atives are frequent, and persistence of positivity may 
be prolonged (4).
CASE REPORT
We report on a 69-year-old-man on chronic HD 
due to diabetes nephropathy, with a history of isch-
emic cardiomyopathy and implanted bypass due to a 
three-vessel coronary heart disease. 
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He was screened because of a positive cluster in his 
dialysis unit. He was found positive for SARS-CoV-2 
by a nasopharyngeal polymerase chain reaction (PCR) 
test on July 22, 2020. Th e patient was isolated and am-
bulatory dialyzed in a special COVID unit. Except for 
fatigue, the patient did not report any other symptoms 
for several days. On the fi rst physical examination, he 
was afebrile and hemodynamically stable (blood pres-
sure 120/70 and heart rate 89 beats/minute) with oxy-
gen saturation of 98%. Auscultatory fi nding on the 
lungs was normal. Complete blood count revealed 
normal fi ndings, with the exception of thrombocyto-
penia, which had been present before (Le 6.1x109, Er 
4.59x1012, Hgb 144 g/l, Plt 91x109 ) and normal values 
of C-reactive protein (CRP; 5 mg/mL). His chest x-ray 
showed a congestive state, which could not completely 
rule out incipient infi ltrative changes and he was ad-
ministered antibiotic therapy with azithromycin 500 
mg for six days. He continued with HD every other 
day and was regularly monitored by a nephrologist. 
During this period, the patient was feeling well and 
was clinically stable. He tested negative on August 3, 
2020 and his isolation measures were discontinued.
On November 11, 2020, the patient’s daughter called 
his dialysis unit to inform that her father was febrile 
and felt fatigue with occasional vomiting. Th e patient 
had a PCR test, which came back positive. On physical 
examination, he was febrile and dyspneic with oxygen 
saturation of 93%, and bilateral basal crackles were 
heard on the lungs. Th e blood count was similar to the 
previous one but increased CRP levels were noticed 
(>120 mg/mL). Now his chest x-ray showed conges-
tive changes and bilateral infi ltration. He continued 
his ambulatory HD treatment in the COVID positive 
unit and there he received antibiotic treatment with 
cephazolin 2 g intravenously (i.v.), but he still felt un-
well. On day 9 of illness, aft er HD he worsened, could 
not breathe, and had severe dyspnea with oxygen sat-
uration of 75% and limb cyanosis. He was urgently 
transported to the COVID Disease Isolation Center. 
Upon arrival, his clinical state worsened with a very 
low oxygen saturation of 42% and he was immediately 
placed on oxygenation. His blood count and CRP were 
the same with azotemia (urea 29.2 mmol/L, creatinine 
899 μmol/L), electrolyte imbalance (Na 128 mmol/L, 
K 5.7 mmol/l, Cl 101 mmol/L), very high values of 
D-dimer (36.5 mg/L) and immeasurable fi brinogen. 
Native computed tomography scan (CT) of the tho-
racic organs showed extensive ground glass opacities 
(GGO) and gentle consolidation of the peripheral and 
basal parts of the lungs. He was administered dexa-
methasone 6 mg i.v., ceft riaxone 2 g i.v., doxycycline 
cps 2x100 mg per os daily, and low molecular weight 
heparin 40 mg twice a day, in addition to the patient’s 
chronic therapy. Th e patient was also on CVVHD 
treatment according to the protocol and under oxy-
genation up to 6 L/min. When the PCR test came neg-
ative a few days later, he was transferred to the Ne-
phrology Department, where his laboratory fi ndings 
were similar to those mentioned above, with high 
LDH level (1098 U/L) and a decrease in CRP (94.4 
-57.7 mg/L), D-dimer (8.05 mg/L) and fi brinogen (2.1 
g/L) values. Control CT showed signifi cant regression 
of the previously observed changes. Serologic testing 
showed an IgG level of 91.4600 AU/mL and IgM of 
14.7200 AU/mL. 
With the given therapy and regular HD treatment, the 
patient gradually recovered but still was weak, hypo-
tensive, and cardiopulmonary compensated. Upon 
discharge, he continued HD in his unit, but his overall 
condition worsened compared to the condition before 
the infection, when he was a clinically stable patient. 
DISCUSSION
To the best of our knowledge, only four cases of 
COVID-19 reinfection in HD patients have been re-
ported. Mendoza et al. (5) presented a case of a clin-
ically manifest infection that followed two months 
aft er detecting low IgG antibody with a negative PCR 
test. Krishna et al. (6) described two patients with 
suspected recurrent COVID-19 infection, each with 
documented clearance of virus between the episodes. 
In these two patients, the time elapsed between the 
negative reverse-transcription PCR test result for 
SARS CoV-2 and symptomatic reinfection was 31 
and 55 days, respectively. Both of these patients were 
tested aft er a contact with a positive person and had 
no symptoms; then, one patient had severe symptoms 
and required hospitalization, whereas the other had 
mild symptoms and was treated as outpatient (6). 
In addition, Torreggiani et al. (4) report on a patient 
who was screened because of a positive cluster in his 
nursing home and tested PCR positive; 22 days af-
ter testing negative, he developed fever and bilateral 
pneumonia. In this case, besides reinfection, the au-
thors highly suspected the occurrence of virus reacti-
vation and inaccuracy of testing (4).
In our case, we could not rule out the possibility of the 
initial false-positive test either. It was quite unlikely 
because the patient lived in a city that recorded a large 
number of infected inhabitants and also had a suspi-
cious contact in his HD unit.
Th e PCR tests for SARS-CoV-2 detection are consid-
ered as the gold standard but are not perfect, especial-
ly in clinical practice because false tests can have fatal 
consequences (7). Technical problems including con-
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tamination during the sampling and cross-reactions 
with other viruses or genetic material may be respon-
sible for false-positive results. When interpreting the 
results, it is important to consider the patient epidemi-
ologic history and previous COVID-19 disease. When 
there is a low probability based on all these data, a 
positive result should be interpreted with caution and 
another test should be performed (8). 
In our case, additional test was not performed aft er the 
fi rst positive PCR test because our patient had a posi-
tive epidemiologic survey. 
Reinfections with other human coronaviruses can oc-
cur, while reinfection with SARS-CoV-2 in humans is 
rare and unknown (9). Selvaraj et al. presented a num-
ber of 34 reinfections recorded worldwide until No-
vember 2020 (10). Most people infected with SARS-
CoV-2 have detectable antibodies for 10-14 days of 
symptom onset, while antibody titer is low or even im-
possible to detect in patients with a mild clinical pic-
ture (11). Th ere is little information about the strength 
and length of protection provided by this immune 
response against future infections (10). One Chinese 
study showed 40% of asymptomatic cases and 12.9% 
of symptomatic patients who became seronegative in 
the early convalescent phase (8 weeks aft er infection) 
(12). Whether these fi ndings of the presence of SARS-
CoV-2 antibodies in patients with CKD is similar to 
the general population is still unknown (13). 
In our case, no serologic testing was performed aft er 
the fi rst positive test, which is a limitation of our re-
port, and we do not know whether the patient devel-
oped antibodies aft er the initial infection or became 
seronegative aft er a certain period. Aft er the second 
infection, serologic testing showed a high amount 
of both IgG and IgM antibodies. Th is goes in favor 
to the fact that infections with mild symptoms have 
lower antibodies and is more likely to get reinfected 
(10). But, opposite to our case where reinfection pre-
sented with severe symptoms, most infections with 
respiratory viruses occur with milder symptoms due 
to a stronger immune system response that can occur 
when reinfection occurs with a diff erent strain of the 
same virus (14). 
Th is case presents the possibility of reinfection, lack 
of immune response aft er mild symptoms, or even 
an initial false-positive test. Based on the previously 
reported cases of reinfection, it is indicative that the 
immunity developed aft er COVID-19 infection can-
not provide lifetime protection. Th ere is also a para-
dox between the decrease in antibody titer that occurs 
over time and the low incidence of reinfections, which 
points to complex immune mechanisms. In order to 
better understand those mechanisms, longitudinal 
studies in the future are needed, as well as a uniform 
diagnostic approach to the patient, which will allow 
better comparison of patients from diff erent hospitals 
and countries.
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Bolesnici s terminalnom bubrežnom bolešću koji su na hemodijalizi (HD) pod visokim su rizikom od zaraze virusom SARS-
CoV-2 i od razvijanja teške kliničke slike bolesti COVID-19. Mogućnost ponovne zaraze ovim virusom još je uvijek većinom 
nepoznata. Do danas je opisan manji broj COVID-19 reinfekcija, pogotovo kod bolesnika na HD gdje su dosad opisana 
samo četiri slučaja. Prikazujemo mogućnost reinfekcije virusom SARS-CoV-2 i razvoja teškog akutnog respiracijskog sin-
droma kod bolesnika na HD. Prikaz bolesnika: Bolesnik u dobi od 69 godina je na kroničnom programu HD tri godine zbog 
bubrežnog zatajenja tijekom dijabetičke nefropatije s anamnezom ishemijske kardiomiopatije te dvostrukim CABG zbog 
trožilne koronarne bolesti. U srpnju 2020. godine bolesnik je testiran pozitivno metodom PCR na SARS-CoV-2 zbog kon-
takta s pozitivnim bolesnikom u zajedničkom prijevozu na dijalizu. U tom je razdoblju imao blage simptome, umor nekoliko 
dana, nakon čega je postao asimptomatičan. Nakon četiri mjeseca javlja se u bolnicu s visokom tjelesnom temperaturom, 
teškom zaduhom i lošim općim stanjem te je opet COVID-19 pozitivan. Zaključak: Ovaj slučaj ukazuje na mogućnost rein-
fekcije, slabog imunosnog odgovora nakon asimptomske ili blage infekcije ili čak prvog lažno pozitivnog PCR testa. Da bi 
se evaluirao potencijalni mehanizam reinfekcija, eventualnih recidiva i trajanje imunosnog odgovora potrebne su buduće 
longitudinalne studije.
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